QuantiScientifics

Executive Summary

QuantiScientifics is a private biotechnology company based in San Diego, specializing in multiplex diagnostic assays for allergen testing, food intolerance, and inflammatory response monitoring. Its proprietary A-squared (A2) oligo-link platform enables the creation of custom antibody microarrays in standard well plates without the need for traditional printing, significantly reducing cost and development time. This technology is adaptable to multiple assay formats including ELISA, lateral flow, and microfluidics, positioning the company to address the growing demand for rapid, point-of-care diagnostics. Founded in 2015, the company has remained under the radar but its platform holds promise for personalized medicine and decentralized testing markets. Although QuantiScientifics has not disclosed funding rounds or revenue, the versatility of its A2 platform could disrupt the conventional microarray market. The company's focus on inflammatory and allergic conditions aligns with rising prevalence of these disorders. The lack of publicly disclosed partnerships or regulatory milestones suggests an early-stage profile, but the technical differentiation and applicability across formats provide a foundation for growth. Given the platform's potential and the large addressable market, QuantiScientifics represents a speculative opportunity with technology risk but significant upside if validation and commercialization milestones are achieved.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for a lead allergen assay50% success
• Q3 2026Strategic partnership with a major diagnostics distributor45% success
• Q2 2026Publication of validation data in a peer-reviewed journal70% success